Charles River Laboratories lands Morgan Stanley upgrade, shares in analyst focus

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-27, 13:33.

Charles River Laboratories (US1591881009) has been highlighted by Morgan Stanley with a rating upgrade in mid-June, reflecting improving sentiment toward biopharma funding and outsourced research services on NASDAQ. The move adds fresh attention to the stock ahead of the next earnings updates from the US life-science tools peer group.

What Morgan Stanley changed

Morgan Stanley’s recent note on the US contract research space singles out Charles River Laboratories alongside IQVIA, with the bank upgrading Charles River while taking a more cautious stance on IQVIA. The analyst team explicitly ties the change to a perceived boost in biopharma funding, which in turn supports demand for preclinical and early-stage research capacity.

According to the Morgan Stanley write-up, Charles River Laboratories benefits from its positioning across discovery, safety assessment and manufacturing services, giving it exposure to a broad range of biotech and pharmaceutical clients. The bank cites improving funding flows into biotech as a driver for a more constructive view on research-outsourcing specialists like Charles River.

Analyst consensus and rating picture

The Morgan Stanley upgrade comes against a backdrop of a broadly positive analyst consensus on Charles River Laboratories. A compilation of Wall Street views in the Morgan Stanley-sourced note refers to 12 analyst ratings on the stock, of which nine are Buy and three are Hold, with no Sell recommendations reported. This distribution points to a predominantly supportive stance among covering analysts on the NASDAQ-listed shares.

The same source references a current Charles River Laboratories share price level around 212.71 US dollars in mid-June, providing context for the upgraded view relative to prevailing market pricing. While individual price targets are not detailed in the Morgan Stanley summary, the imbalance between Buy and Hold ratings underscores a constructive bias in the coverage universe. For investors tracking the life-science tools space, the analyst structure around Charles River sits broadly in line with other US research service providers.

The business behind the stock

Charles River Laboratories generates its revenue by providing contract research, non-clinical development and manufacturing services to pharmaceutical, biotechnology and academic customers worldwide. The company’s portfolio spans discovery services, safety assessment, laboratory animal models and cell and gene therapy manufacturing, positioning it as a key infrastructure provider to the biopharma sector.

Where the shares trade today

The Charles River Laboratories shares (US1591881009) trade on NASDAQ, with recent June pricing referenced at around 212.71 US dollars in the Morgan Stanley-related note. This level serves as a context point for the analyst upgrade and the broader consensus stance on the stock.

Disclaimer: This article is for informational purposes only and does not contain any investment advice, recommendation or solicitation to buy or sell securities.